NEWLINK GENETICS CORP Development Agreements
27 Contracts & Agreements
- FIRST AMENDED AND RESTATED CELL THERAPY DEVELOPMENT, MANUFACTURING AND/OR TISSUE PROCESSING TERMS AND CONDITIONS BETWEEN WuXi AppTec, Inc. and NewLink Genetics Corporation (Filed With SEC on February 29, 2016)
- Amendment to Development and Manufacturing Terms and Conditions (Filed With SEC on November 10, 2014)
- Development and Process Transfer Program Leading to Commercial Manufacturing for algenpantucel-L HyperAcute" Pancreas Technical Transfer, Verification / Process Development,... (Filed With SEC on August 5, 2014)
- CELL THERAPY DEVELOPMENT, MANUFACTURING AND/OR TISSUE PROCESSING TERMS AND CONDITIONS BETWEEN WuXi AppTec, Inc. and NewLink Genetics Corporation (Filed With SEC on August 5, 2014)
- PUBLIC HEALTH SERVICE COOPERATIVE RESEARCH AND DEVELOPMENT AGREEMENT FOR EXTRAMURAL-PHS CLINICAL RESEARCH (Filed With SEC on May 10, 2012)
- AMENDMENT #2 To Letter of Intent for Proposed CRADA #2166 Pre-Clinical and Clinical Development of [*] (Filed With SEC on November 8, 2011)
- AMENDMENT #1 To Letter of Intent for Proposed CRADA #2166 Pre-Clinical and Clinical Development of [*] (Filed With SEC on November 8, 2011)
- AMENDMENT #8 To Letter of Intent for Proposed CRADA #02166 Preclinical and Clinical Development of 1-Methyl-[d]-Tryptophan as an Anti-Cancer Agent (Filed With SEC on October 4, 2011)
- AMENDMENT #7 To Letter of Intent for Proposed CRADA #2166 Preclinical and Clinical Development of 1-Methyl [d]-Tryptophan as an Anticancer Agent (Filed With SEC on October 4, 2011)
- AMENDMENT #6 To Letter of Intent for Proposed CRADA #2166 Preclinical and Clinical Development of 1-Methyl [d]-Tryptophan as an Anticancer Agent (Filed With SEC on October 4, 2011)
- AMENDMENT #5 To Letter of Intent for Proposed CRADA #2166 Preclinical and Clinical Development of 1-Methyl [d]-Tryptophan as an Anticancer Agent (Filed With SEC on October 4, 2011)
- AMENDMENT #4 To Letter of Intent for Proposed CRADA #2166 Preclinical and Clinical Development of 1-Methyl [d]-Tryptophan as an Anticancer Agent (Filed With SEC on October 4, 2011)
- AMENDMENT #3 To Letter of Intent for Proposed CRADA #2166 Preclinical and Clinical Development of 1-Methyl [d]-Tryptophan as an Anticancer Agent (Filed With SEC on October 4, 2011)
- AMENDMENT #2 To Letter of Intent for Proposed CRADA #2166 Pre-Clinical and Clinical Development of 1-Methyl-[d]-Tryptophan as an Anti-Cancer Agent (Filed With SEC on October 4, 2011)
- AMENDMENT #1 To Letter of Intent for Proposed CRADA #2166 Pre-Clinical and Clinical Development of 1-Methyl-[d]-Tryptophan as an Anti-Cancer Agent (Filed With SEC on October 4, 2011)
- DEPARTMENT OF THE ARMY U.S. ARMY RESEARCH, DEVELOPMENT AND ENGINEERING COMMAND ACQUISITION CENTER RESEARCH TRIANGLE PARK DIVISION P.O. BOX 12211 RESEARCH TRIANGLE PARK, NORTH... (Filed With SEC on February 28, 2011)
- DEPARTMENT OF THE ARMY U.S. ARMY RESEARCH, DEVELOPMENT AND ENGINEERING COMMAND ACQUISITION CENTER (Filed With SEC on February 28, 2011)
- DEPARTMENT OF THE ARMY U.S. ARMY RESEARCH, DEVELOPMENT AND ENGINEERING COMMAND ACQUISITION CENTER (Filed With SEC on February 28, 2011)
- AMENDMENT #7 To Letter of Intent for Proposed CRADA #2166 Preclinical and Clinical Development of [*] (Filed With SEC on February 28, 2011)
- $6,000,000 IOWA VALUES FUND (IVF) CONTRACT BY AND BETWEEN NEWLINK GENETICS CORPORATION AND THE IOWA DEPARTMENT OF ECONOMIC DEVELOPMENT DATED AS OF MARCH 18, 2005 (Filed With SEC on December 21, 2010)
- AMENDMENT #6 To Letter of Intent for Proposed CRADA #2166 Preclinical and Clinical Development of [*] (Filed With SEC on December 21, 2010)
- AMENDMENT #5 To Letter of Intent for Proposed CRADA #2166 Preclinical and Clinical Development of [*] (Filed With SEC on December 21, 2010)
- AMENDMENT #4 To Letter of Intent for Proposed CRADA #2166 Preclinical and Clinical Development of [*] (Filed With SEC on December 21, 2010)
- AMENDMENT #3 To Letter of Intent for Proposed CRADA #2166 Preclinical and Clinical Development of [*] (Filed With SEC on December 21, 2010)
- AMENDMENT #2 To Letter of Intent for Proposed CRADA #2166 Pre-Clinical and Clinical Development of [*] (Filed With SEC on December 21, 2010)
- AMENDMENT #1 To Letter of Intent for Proposed CRADA #2166 Pre-Clinical and Clinical Development of [*] (Filed With SEC on December 21, 2010)
- Cooperative Research and Development Agreement (CRADA #1901) [*] NCI Principal Investigator John C. Morris, M.D. Metabolism Branch, CCR, NCI Collaborator PrincipalInvestigator... (Filed With SEC on December 21, 2010)
